Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11159 Views
-
Last post by NHE
-
- 0 Replies
- 1035 Views
-
Last post by NHE
-
- 0 Replies
- 1835 Views
-
Last post by frodo
-
- 0 Replies
- 1196 Views
-
Last post by frodo
-
- 0 Replies
- 1966 Views
-
Last post by NHE
-
- 0 Replies
- 1659 Views
-
Last post by frodo
-
- 0 Replies
- 1175 Views
-
Last post by NHE
-
- 1 Replies
- 1657 Views
-
Last post by frodo
-
- 0 Replies
- 2223 Views
-
Last post by NHE